AbbVie (NYSE: ABBV) experienced a share price decline of approximately 4% following the release of its third-quarter earnings report. While the pharmaceutical giant posted robust results, they fell short of heightened investor expectations for even stronger growth, triggering a temporary sell-off. However, analysts highlight the company’s powerful core product growth and reliable dividend as pillars supporting its long-term investment case.
The earnings report, released on October 31, revealed Q3 revenue of $15.8 billion, a 9.1% year-over-year increase. This high-single-digit growth demonstrates AbbVie’s resilience even after the patent expiration of its former top-selling drug, Humira. Adjusted earnings per share (EPS) were $1.86, down 38% primarily due to acquisition-related costs. Despite this, the company raised its full-year 2025 adjusted EPS guidance to a range of $10.61-$10.65.
Nevertheless, the market was not fully satisfied with this “steady” performance. Some investors had anticipated more robust growth figures, particularly from newer star products and drug advancements. The immediate stock drop reflected this short-term sentiment shift.
Despite the near-term volatility, AbbVie’s underlying business remains strong. Its core immunology drugs, Skyrizi and Rinvoq, were standout performers. The duo generated combined revenue of $6.9 billion in the quarter, surging more than 40% year-over-year. The company now expects these products to achieve over $31 billion in annual revenue by 2027, an increase of $4 billion from prior forecasts. Furthermore, AbbVie has secured patent agreements that delay biosimilar competition for Rinvoq in the U.S. until 2037, ensuring a durable revenue stream.
Beyond its immunology stars, AbbVie is making strides in the migraine treatment space with products like Qulipta and Ubrelvy. It is also actively expanding into the weight-loss drug market, recently acquiring rights to an early-stage candidate, GUB014295. With approximately 50 mid- and late-stage pipeline projects, the company’s future growth drivers appear well-supported.
As a “Dividend King” having raised its payout for 53 consecutive years, AbbVie is a favorite for long-term, income-focused investors. Since its spin-off from Abbott in 2013, the company’s dividend has grown by a cumulative 332.5%. Its forward dividend yield stands at approximately 3.1%, significantly above the S&P 500’s average of 1.2%. Additionally, the stock trades at a forward P/E ratio of just 16.1x, below the healthcare sector average of 17.9x, indicating a potential valuation advantage.
Market analysts suggest that AbbVie has successfully navigated the post-Humira patent cliff and is transitioning into a new growth phase through product diversification. They view the recent stock pullback as a potential entry point for long-term investors. An analyst from Futu Securities noted that AbbVie’s leading position in immunology, its innovative pipeline, and its high-dividend defensive qualities collectively underpin the stock’s long-term value.
